More States Move to Expand Bans on 'Gas Station Morphine'

States across the United States are rapidly expanding emergency and legislative bans on tianeptine, an unapproved drug often marketed as a dietary supplement and nicknamed “gas station morphine” for its opioid-like effects and easy availability at convenience stores.

From Niche Supplement to Public Health Flashpoint

Tianeptine has been sold for years in the United States as a capsule, liquid shot or powder, frequently labeled as a supplement to improve mood, focus or brain function. Publicly available information shows that the substance is approved as an antidepressant in parts of Europe, Asia and Latin America, but it has never been authorized for any medical use in the U.S. despite aggressive marketing at gas stations, vape shops and online retailers.

Health agencies and poison control centers have documented a rising pattern of adverse events linked to tianeptine, including reports of seizures, loss of consciousness and symptoms consistent with opioid withdrawal. Federal health advisories describe the drug as having opioid-like properties that can lead to dependence, misuse and overdose, particularly when taken in high doses or combined with other substances.

The products are often sold under colorful brand names and packaged alongside energy shots and herbal supplements, which critics say obscures their risks. According to published coverage and state health bulletins, tianeptine items are frequently promoted with unsupported claims that they can treat anxiety, depression, pain or even opioid use disorder itself, despite lacking any approval or standardized dosing.

As concerns have intensified, state regulators have begun treating tianeptine not as a fringe wellness product but as part of the broader opioid landscape, drawing comparisons with previous waves of synthetic drugs that initially slipped through regulatory gaps.

Emergency Bans Give Way to Broader State Crackdowns

Several states first addressed tianeptine through emergency actions, using expedited authority to suspend normal rulemaking and place the substance in the most restrictive schedules of their controlled substances laws. Public documents from state boards of pharmacy describe emergency classifications that effectively made sales of tianeptine products illegal, especially in retail environments such as gas stations and corner stores.

Those initial steps are now being followed by permanent statutes and broader enforcement campaigns. Reports indicate that legislatures in multiple states have advanced or passed bills explicitly targeting so-called “gas station drugs,” including tianeptine and certain synthetic kratom-derived compounds, citing a need to move quickly before the products become further entrenched in local markets.

In some jurisdictions, emergency restrictions have expanded into coordinated sweeps of convenience outlets. Recent enforcement operations in the Southeast, for example, have focused on seizing unapproved opioid-like products from gas stations and wholesale distributors, with authorities highlighting test results that confirm the presence of potent compounds capable of producing strong opioid effects.

Policy analysts note that the pace of state-level scheduling is accelerating as more legislatures convene in 2026, transforming what began as isolated emergency orders into a patchwork of comprehensive bans that retailers are increasingly required to navigate.

Consumer Warnings Highlight Overdose and Addiction Risks

Federal and state health agencies have issued repeated consumer alerts urging people to avoid tianeptine products entirely. Public advisories describe cases of severe toxicity, including hospitalizations and deaths where tianeptine or closely related compounds were a significant factor, and warn that labels often omit or misrepresent ingredients.

According to trend reports from state health departments, emergency department visits associated with tianeptine exposure have risen in recent years, particularly in regions where the drug remained legal and widely available in convenience retail. Some of these reports describe patients presenting with confusion, rapid heart rate, extreme agitation or sudden withdrawal symptoms after attempting to stop high-dose use.

National organizations focused on controlled substances policy have also called out tianeptine in recent resolutions, describing it as an urgent public health threat because of its marketing in everyday retail locations and its lack of any recognized therapeutic role in the U.S. These groups emphasize that the substance is often promoted as a natural or legal alternative to opioids, even as evidence points to similar patterns of dependence and withdrawal.

Alongside enforcement and scheduling, regulators are encouraging retailers to voluntarily remove products that contain tianeptine or similar opioid-like ingredients, warning that liability may increase as more states define the drugs as controlled substances.

Retailers Caught Between Patchwork Rules and Profit Pressures

The expanding bans are reshaping the landscape for convenience stores, independent gas stations and vape shops, which have increasingly relied on high-margin supplements and novelty products to bolster revenue. Industry observers note that many small retailers may not have in-house compliance expertise, leaving them vulnerable to stocking items that later become prohibited.

Trade publications and regional news coverage show that some chains have proactively cleared their shelves of tianeptine and related products in response to state advisories, while others have been the subject of raids or inspections resulting in product seizures and potential civil penalties. In states where bans are newly enacted or still moving through legislatures, the result is a patchwork of rules that can vary sharply between neighboring jurisdictions.

Retail associations have urged their members to pay close attention to state board of pharmacy notices, attorney general bulletins and controlled substances updates, pointing out that many of the products in question are marketed under shifting brand names that may not clearly reference tianeptine on front labels. Compliance specialists recommend that store owners scrutinize inventory lists from distributors and avoid items that claim opioid-like relief or dramatic mood enhancement without recognized regulatory approval.

For communities that have already seen overdose deaths linked to gas station drugs, local leaders are pressing for more direct outreach to small retailers, arguing that awareness campaigns can be as important as headline-grabbing enforcement actions in reducing availability.

Policy Debate: Harm Reduction vs. Prohibition

The rapid move to restrict tianeptine is unfolding alongside broader shifts in U.S. drug policy, where many states are experimenting with harm reduction tools while also tightening controls on emerging synthetic substances. Recent regulatory decisions allowing over-the-counter sales of naloxone nasal sprays at pharmacies and convenience stores are viewed by public health advocates as a counterweight to the risks posed by unregulated opioid-like products in the same locations.

Some experts argue that emergency bans on tianeptine are necessary to prevent a new wave of dependence, especially among people seeking inexpensive relief from anxiety, pain or opioid withdrawal outside the medical system. Others warn that focusing solely on prohibition may push demand toward even less understood substances, repeating cycles seen with past crackdowns on designer drugs.

Analysts following statehouse debates say a growing number of lawmakers are seeking middle-ground approaches that pair scheduling actions with expanded access to evidence-based treatment, overdose-reversal medications and public education about the dangers of gas station drugs. In this view, restricting tianeptine is one component of a wider effort to keep up with a rapidly evolving market for psychoactive products that often appear far from traditional drug settings.

As more states move to expand emergency bans into long-term policy, the trajectory of “gas station morphine” may serve as a test case for how quickly regulators, retailers and health systems can respond to the next wave of unapproved, opioid-like substances entering the consumer marketplace.